IORT Special Report:
Advancing the Treatment of Breast Cancer and the Role of Intra-Operative Single Dose Therapy
Learn more about the benefits and global adoption of IORT technology for breast applications with the ‘IORT Special Report’ - featuring a collection of peer-reviewed articles.
Simply fill in your details below for your free copy:
ZEISS INTRABEAM 600
Melding two worlds into one benefit
Combining surgery and radiotherapy, ZEISS INTRABEAM 600 enables an individual IORT treatment ensuring that skin and deeper structures are protected and a shorter duration of the radiation therapy compared to external beam radiation therapy (EBRT). This can also reduce associated side effects and enhances treatment comfort for the patient – a key element in increased quality of life.1
1 Vaidya, J. S. et al. (2020). Long-term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ, 370, m2836. https://doi.org/10.1136/bmj.m2836
Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development.